跳至主要内容

Pharmaceutical Development Services

 Medicilon has been offering high quality analytical testing services to the pharmaceutical industry for decades. We offer a wide range of quality control testing services to support drug research, registration and production. Biopharmaceutical companies also use many of the same services and Medicilon has also added new services to accommodate their unique needs (detailed in the following section).

We perform a variety of tests that are client-specific, particularly in the area of analytical chemistry. Please inquire for more information about additional tests we perform that may not be listed in this brochure.



Laboratory Services

GLP and GCP Bioanalytical Services & Biomarkers
GMP and CMC Laboratory Services
Pharmaceutical Analysis, Stability and Formulation Development Extractables/Leachables Packaging Support
Process Development and Manufacturing Analysis Support

Bioanalytical Services

Our teams are adept in method development,method validation and transfer of efficient and accurate methods which are optimized for your compound. Projects are assigned to and managed by experienced Principal Investigators with support from teams of Project Managers, Project Coordinators, Senior Scientists and Chemists. We provide:

• Bioanalysis for Large and Small Molecules
• Immunogenicity & Neutralizing Antibody Assays
• Antibody Drug Conjugate (ADC) LC-MS and Immunochemistry Services
• Long History of Bioanalytical Support for Biosimilar Drug Development
• Post Marketing Antidrug Antibody (ADA) assays
• Demonstrated Expertise in Ocular Tissue

GMP and Chemistry, Manufacturing & Controls (CMC) Laboratory Services

• GMP Pharmaceutical Analysis
• Method Development & Validation
• Biopharmaceutical CMC Solutions
• GMP Stability Studies
• GMP Batch Release Testing
• Extractables / Leachables
• Glass Delamination Studies
• Elemental Impurities
• Formulation Development
• Preformulation and Physical Characterisation
• GMP Quality Control Testing
• Reference Standard Certification
• Impurities and Particulates Analysis
• Clinical Trial Supplies Manufacturing Services
• Regulatory Affairs
• GMP Auditing and Supply Chain Assurance
• GMP Training Sessions and eLearning For Staff

ANALYTICAL CHEMISTRY
Medicilon provides the professional expertise and regulatory qualifications necessary to perform analytical testing of raw materials, APIs, finished products, packaging material and medical devices. Well-equipped state-of-the-art laboratories offer comprehensive testing services according to the pharmacopoeia and to customer specifications.

STABILITY STUDIES
With a network of ICH stability storage facilities, we offer an extensive capacity and a range of conditions including climatic walk-in chambers and cabinets as well as freezer storage. Our stability teams provide professionally managed cGMP stability programs for even the most complex of dosage forms including orally inhaled and nasal drug products (OINDP), biopharmaceuticals, medical devices or vaccines.

PREFORMULATION
Our team of chemical and formulation development scientists work together to fully understand the physiochemical properties of your drug substance prior to formulating an optimum drug product for clinical supplies, using:

• Polymorph Screening, Crystal Engineering & Crystal Form Selection
• Physiochemical Characterization of API
• Excipient Compatibility Studies

NON-GMP DEVELOPMENT

Our non-GMP development services offer you greater flexibility and speed. With a state of-the-art facility, we are able to focus on lab-scale experiments with batch sizes ranging from <1kg up to approximately 5kg scale for most technologies.

With both our non-GMP and GMP facilities residing on the same campus, we can provide a seamless transition between the development and GMP phases of projects in early stage development.

Biopharmaceutical Services

Our thought-leaders have over 12 years of experience in biopharmaceutical development support across a wide range of product types. Our experts provide regulatory led, phase-appropriate, tailored analytical program design and GLP or GMP compliant laboratory services which help you to navigate the challenges of development, regulatory submission and manufacturing.

Biopharmaceutical Development Support

• GLP Preclinical Bioanalysis
• Immunogenicity Studies
• Analytical Program Design
• Structural Characterization (ICH Q6B)
• Physicochemical Properties (ICH Q6B)
• Comparability Studies
• Biosimilar Programes
• Process Residuals Determination
• Product Related Impurities Determination
• Aggregation Studies
• GMP Potency / Cell Based Assays
• Method Development & Validation
• Extractables / Leachables
• GMP Quality Control Testing
• GMP Batch & Final Product Release Testing
• ICH Stability Studies
• Forced Degradation Studies

• Drug Delivery / OINDP Expertise

Contact Us 

Email : marketing@medicilon.com

Tel : +44 1223 981 792（Europe）

+82 (0)70-8269-5849（South Korea）

08044216898（Japan）

+86 021 58591500（China )

Website: https://www.medicilon.com

 

Tips : Above is part of pharmaceutical development services, pharmaceutical product development, pharmaceutical development. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

Related Articles:

Pharmaceutical Preformulation Studies

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文